GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Total Inventories

Hansa Biopharma AB (OSTO:HNSA) Total Inventories : kr1.2 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Total Inventories?

Hansa Biopharma AB's total inventories for the quarter that ended in Mar. 2024 was kr1.2 Mil. Hansa Biopharma AB's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was kr1.4 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Hansa Biopharma AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was kr-11.55.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Hansa Biopharma AB's Days Inventory for the three months ended in Mar. 2024 was 6.82.

Inventory Turnover measures how fast the company turns over its inventory within a year. Hansa Biopharma AB's Inventory Turnover for the quarter that ended in Mar. 2024 was 13.38.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Hansa Biopharma AB's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.02.


Hansa Biopharma AB Total Inventories Historical Data

The historical data trend for Hansa Biopharma AB's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Total Inventories Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.10 0.24 0.97 1.51

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 2.50 3.12 1.51 1.20

Hansa Biopharma AB Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Hansa Biopharma AB  (OSTO:HNSA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Hansa Biopharma AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(541.465+0.75 * 72.596+0.5 * 1.201-1204.759
-0-0)/52.6718
=-11.55

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Hansa Biopharma AB's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=1.357/18.158*365 / 4
=6.82

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Hansa Biopharma AB's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=18.158 / 1.357
=13.38

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Hansa Biopharma AB's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=1.357 / 55.981
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Hansa Biopharma AB Total Inventories Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines